Neurodegeneration specialist achieves over 50% enrollment in Phase 1b PRECISE-AD trial

ProMIS Neurosciences announced significant progress in its 128-patient Phase 1b PRECISE-AD trial for Alzheimer’s disease, with enrollment exceeding 50% of the target population.

The strong recruitment momentum reflects both the urgent need for new Alzheimer’s treatments and the appeal of ProMIS’ novel approach targeting toxic oligomers of amyloid beta and tau proteins.

Scientific Approach: ProMIS’ platform identifies highly selective antibodies against the most toxic forms of disease-causing proteins, potentially offering advantages over broader approaches that have failed in previous Alzheimer’s trials.

The PRECISE-AD trial design allows for comprehensive evaluation of safety, tolerability, and early efficacy signals in mild-to-moderate Alzheimer’s patients, providing crucial data for advancing the program toward larger pivotal studies.

Enrollment Success Factors: The rapid recruitment likely reflects improved clinical trial infrastructure for Alzheimer’s research and increased patient and family willingness to participate in studies following recent FDA approvals of other amyloid-targeting therapies.

Reaching the 50% enrollment milestone positions ProMIS to complete the trial on schedule and generate meaningful data for the Alzheimer’s development community.